2013
Klein F.*, Diskin R.*, Schied JF., Gaebler C., Mouquet H., Georgiev I., Pancera M., Zhou T., Incesu RB., Fu BZ., Gnanapragasam PN., Oliveira TY., Seaman MS., Kwong PD., Bjorkman PJ.@, Nussenzweig MC.@, Cell (accepted manuscript), “Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization”.
- Equally contributed authors * and @
Hoot S., McGuire AT., Cohen KW., Strong RK., Hangartner L., Klein F., Diskin R., Scheid JF., Sather DN., Burton DR., Stamatatos L., PLoS Pathog. 2013 Jan;9(1):e1003106. Epub 2013 Jan 3. “Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs”. PubMed
2012
Klein F., Halper-Stromberg A., Horwitz JA., Gruell H., Scheid JF., Bournazos S., Mouquet H., Spatz LA., Diskin R., Abadir A., Zang T., Dorner M., Billerbeck E., Labitt RN., Gaebler C., Marcovecchio PM., Incesu RB., Eisenreich TR., Bieniasz PD. Seaman MS., Bjorkman PJ., Ravetch JV., Ploss A. & Nussenzweig MC., 2012, Nature, Epub 2012 October 24. “HIV therapy by a combination of broadly neutralizing antibodies in humanized mice”. PubMed
Pietzsch J., Gruell H., Bournazos S., Donovan BM., Klein F., Diskin R., Seaman MS., Bjorkman PJ., Ravetch JV., Ploss A., Nussenzweig MC., 2012 Proc Natl Acad Sci; 109(39):15859-64. Epub 2012 Sep 10. “A mouse model for HIV-1 entry”. PubMed
West, A. P., Diskin R., Nussenzweig MC., Bjorkman PJ., 2012, Proc Natl Acad Sci 109(30):E2083–E2090 “Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120”. PubMed
2011
Diskin R., Scheid JF., Marcovecchio PM., West, A. P., Klein F., Gao H., Gnanapragasam PNP., Abadir A., Seaman MS., Nussenzweig MC., Bjorkman PJ., 2011, Science 334:1289-93 “Increasing the Potency and Breadth of an HIV Antibody by using Structure-Based Rational Design”. PubMed
- This article was featured online ahead of print through Science Express (October 27th).
Scheid JF., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira TY., Pietzsch J., Fenyo D., Abadir A., Velinzon K., Hurley A., Myung S., Boulad F., Poignard P., Burton DR., Pereyra F., Ho DD., Walker BD., Seaman MS., Bjorkman PJ., Chait BT., Nussenzweig MC., 2011, Science 333:1633-7 “Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding”. PubMed
2010
Tzarum N., Diskin R., Engelberg D., Livnah O., 2010, J. Mol. Biol., 405(5):1154-69 “Active mutants of the TCR-mediated p38α alternative activation site show changes in the phosphorylation lip and DEF site formation”. PubMed
Diskin R., Marcovecchio PM., Bjorkman PJ., 2010, Nat. Struct. Mol. Biol., 17(5):608–613 “Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity”. PubMed
- This article was featured on the cover of the May issue of Nature Structural and Molecular Biology.
- The article was reviewed in the News and Views section of the May issue by Barton Haynes (Haynes BF. et al. 2010, Nat. Struct. Mol. Biol., 17(5):543-545 “HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?”).
- The article was selected for Faculty of 1000 Medicine by Eric Hunter.
2008 and earlier
Arnon TI., Kaiser JT., West AP Jr., Olson R., Diskin R., Viertlboeck BC., Göbel TW., Bjorkman PJ., 2008, J. Mol. Biol., 381(4):1012-24 “The crystal structure of CHIR-AB1: a primordial avian classical Fc receptor”. PubMed
Diskin R., Engelberg D. and Livnah O., 2008, J. Mol. Biol., 375(1):70-9 “A Novel Lipid Binding Site formed by the MAP Kinase Insert in p38α”. PubMed
Avitzour M., Diskin R., Raboy B., Engelberg D. and Livnah O., 2007, FEBS J., 274(4):963-75 “Intrinsically Active Variants of all Human p38 Isoforms”. PubMed
Diskin R., Engelberg D. and Livnah O., 2007, Acta Crystallogr. D 63, 260-265 “High resolution diffracting crystals of intrinsically active p38α MAP kinase: A case study for low-throughput approaches”. PubMed
Askari N., Diskin R., Avitzour M., Capone R., Livnah O. and Engelberg D., 2007, J. Biol. Chem., 282(1):91-9 “Hyperactive Variants of p38α Induce Whereas Hyperactive Variants of p38γ Suppress AP-1-Mediated Transcription”. PubMed
Diskin R., Lebendiker M., Engelberg D. and Livnah O., 2007, J. Mol. Biol., 365(1):66-76 “Structures of p38α Active Mutants Reveal Conformational Changes in L16 loop that Induce Autophosphorylation and Activation”. PubMed
Friedmann Y., Shriki A., Bennett E. R., Golos S., Diskin R, Bengal E. and Engelberg D., 2006, Mol. Pharmacol., 70(4):1395-405 “JX401, a p38α inhibitor, containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast”. PubMed
Askari N., Diskin R., Avitzour M., Yaakov G., Livnah O., Engelberg D., 2006, Mol. Cell. Endocrinol., 252(1-2):231-40., “MAP-quest: Could we produce constitutively active variants of MAP kinases?”. PubMed
Diskin R., Askari N., Capone R., Engelberg D. and Livnah O., 2004, J. Biol. Chem., 279(45):47040-49 “Active mutants of the p38α Mitogen Activated Protein kinase”. PubMed